Madrigal Pharmaceuticals, Inc.: Form 10-K/A for the period ended Dec 31, 2022
Filed with the SEC on Mar 3, 2023 and accepted by EDGAR at Mar 3, 2023, 16:17 ET.
Sections
No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Operating income | 3 months2022-10-01 to 2022-12-31 | −$85.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months2022-01-01 to 2022-12-31 | −$293.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2022-10-01 to 2022-12-31 | $1.7m | us-gaap:InterestExpense |
| Interest expense | 12 months2022-01-01 to 2022-12-31 | $4.0m | us-gaap:InterestExpense |
| Income tax | 12 months2022-01-01 to 2022-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-10-01 to 2022-12-31 | −$85.9m | us-gaap:NetIncomeLoss |
| Net income | 12 months2022-01-01 to 2022-12-31 | −$295.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-10-01 to 2022-12-31 | −$4.98 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months2022-01-01 to 2022-12-31 | −$17.23 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-10-01 to 2022-12-31 | −$4.98 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months2022-01-01 to 2022-12-31 | −$17.23 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-10-01 to 2022-12-31 | 17,237,517 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 12 months2022-01-01 to 2022-12-31 | 17,137,201 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2022-01-01 to 2022-12-31 | −$224.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2022-01-01 to 2022-12-31 | $217.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2022-12-31 | $331.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-12-31 | $361.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-12-31 | $362.6m | us-gaap:Assets |
| Current liabilities | At period end2022-12-31 | $115.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-12-31 | $165.2m | us-gaap:Liabilities |
| Long-term debt | At period end2022-12-31 | $49.3m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2022-12-31 | $197.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001193125-23-060052. Last ingested by Listed: Nov 6, 2026, 18:49 ET. Listed shows no prices and gives no investment advice.